Smith & Nephew Announces Managerial Stock Transactions

Smith & Nephew Snats ( (SNN) ) has provided an announcement.

On June 6, 2025, Smith & Nephew plc announced transactions involving its directors and persons discharging managerial responsibilities (PDMRs) under the company’s Employee Stock Purchase Plan. These transactions, which took place on June 4, 2025, involved the purchase of American Depository Shares through the company’s Dividend Re-Investment Plan following the final dividend payment for 2024. This notification, made in accordance with UK Market Abuse Regulation, highlights the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting stakeholder confidence and market perception.

The most recent analyst rating on (SNN) stock is a Hold with a $27.71 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats is well-positioned due to strong financial performance and positive earnings call sentiment, highlighting growth and strategic execution. The technical analysis indicates a strong upward trend, although overbought conditions may pose short-term risks. The high P/E ratio suggests potential overvaluation, but the dividend yield adds some appeal for income-focused investors.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a global medical technology company that specializes in the development and manufacturing of advanced medical devices, including orthopaedic reconstruction, trauma, sports medicine, and advanced wound management products. The company is focused on providing innovative solutions to improve patient outcomes and operates in various international markets.

Average Trading Volume: 835,362

Technical Sentiment Signal: Buy

Current Market Cap: $12.86B

Learn more about SNN stock on TipRanks’ Stock Analysis page.